Skip Navigation

FS-3.2 Data Details

FS-3.2 Prevent an increase in the proportion of nontyphoidal Salmonella isolates from humans that are resistant to ceftriaxone (third-generation cephalosporin)

About the Data

Description of the data source, numerator, denominator, survey questions, and other relevant details about the national estimate.

National Data Source
National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS); Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (CDC/NCEZID)
Changed Since the Healthy People 2020 Launch
Baseline (Year)
3.0 (2006-2008)
Target-Setting Method
Maintain the baseline value.
Number of non-typhoidal Salmonella isolates that are resistant to ceftriaxone
Number of non- typhoidal Salmonella isolates tested for resistance to ceftriaxone
Data Collection Frequency
Comparable Healthy People 2010 Objective
Adapted from HP2010 objective
Methodology Notes

The primary objectives of NARMS are to:

  1. Monitor trends in antimicrobial resistance among foodborne bacteria from humans, retail meats, and animals
  2. Disseminate timely information on antimicrobial resistance to promote interventions that reduce resistance among foodborne bacteria
  3. Conduct research to better understand the emergence, persistence, and spread of antimicrobial resistance
  4. Assist the FDA in making decisions related to the approval of safe and effective antimicrobial drugs for animals

In 1996, surveillance for Salmonella in NARMS began in 14 sites. Since 2003, all 50 states have been participating, which represent a population of approximately 308 million (US census, 2010). Participating sites forward every Salmonella Typhi isolate, every twentieth non-typhoidal Salmonella, every twentieth Shigella isolate, and every twentieth E. coli O157 isolate received at their public health laboratories to NARMS at CDC for susceptibility testing.

Susceptibility testing involves determination of minimum inhibitory concentrations for 15 antimicrobial agents: amikacin, ampicillin, amoxicillin-clavulanic acid, cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic acid, streptomycin, sulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole. Resistance in non-typhoidal Salmonella is used for this objective. Non-typhoidal Salmonella excludes the following Salmonella serotypes: Typhi, Paratyphi A, Paratyphi B (i.e., tartrate negative isolates), and Paratyphi C. Tartrate positive Salmonella serotype Paratyphi B isolates are referred to as Salmonella serotype Paratyphi B var. L(+) tartrate+ and are not typically associated with typhoidal disease.

Changes Between HP2010 and HP2020
This objective differs from Healthy People 2010 objective 10-3b in that the word “species” was omitted from the Healthy People 2020 objective to reflect current Salmonella nomenclature. Typhoidal isolates are not included in the Healthy People 2020 objective because they are associated with international travel. Ceftriaxone is tracked in Healthy People 2020 rather than the generic third-generation cephalosporins. Ceftriaxone is particularly important in the treatment of life-threatening Salmonella infection in children.


Additional resources about the objective.

  1. National Antimicrobial Resistance Monitoring System for Enteric Bacteria